Safety and efficacy of alamifovir in patients with chronic hepatitis B virus infection

Journal of Hepatology

Volumn 41, Issue 5, 2004, Pages 852-858

  Soon, Danny K W ^a   Lowe, Stephen L ^a   Teng, Choo Hua ^a   Yeo, Kwee Poo ^a   McGill, James ^b   Wise, Stephen D ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Alamifovir; HBV DNA; HBV patients

Indexed keywords

ALAMIFOVIR; ANTIVIRUS AGENT; UNCLASSIFIED DRUG; VIRUS DNA;

ABDOMINAL PAIN; ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; FEVER; FOLLOW UP; HEADACHE; HEPATITIS B; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOMNOLENCE; VERTIGO; VIRUS LOAD;

ADMINISTRATION, ORAL; ADULT; ANTIVIRAL AGENTS; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B, CHRONIC; HUMANS; MALE; MIDDLE AGED; PURINES; TREATMENT OUTCOME;

EID: 7244248967     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2004.07.028     Document Type: Article

References (20)

1. A.S. Lok, and B.J. McMahon Practice Guidelines Committee, American Association for the Study of Liver Diseases. Chronic hepatitis B Hepatology 34 2001 1225 1241
2. J.L. Dienstag, E.R. Schiff, M. Mitchell, D.E. Casey Jr, N. Gitlin, and T. Lissoos Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy Hepatology 30 1999 1082 1087
3. Y.F. Liaw Impact of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B Antivir Chem Chemother 12 2001 67 71
4. N.W. Leung, C.L. Lai, T.T. Chang, R. Guan, C.M. Lee, and K.Y. Ng Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy Hepatology 33 2001 1527 1532
5. S.J. Hadziyannis, N.C. Tassopoulos, E.J. Heathcote, T.T. Chang, G. Kitis, and M. Rizzetto Adefovir Dipivoxil 438 Study Group. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B N Engl J Med 348 2003 800 807
6. P. Marcellin, T.T. Chang, S.G. Lim, M.J. Tong, W. Sievert, and M.L. Shiffman Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B N Engl J Med 348 2003 808 816
7. M.E. Mailliard, and J.L. Gollan Suppressing hepatitis B without resistance - so far, so good N Engl J Med 348 2003 848 850
8. K. Sekiya, H. Takashima, N. Ueda, N. Kamiya, S. Yuasa, and Y. Fujimura 2-Amino-6-arylthio-9-[2-(phosphonomethoxy)ethyl]purine bis(2,2,2-trifluoroethyl) esters as novel HBV-specific antiviral reagents J Med Chem 45 2002 3138 3142
9. N. Kamiya, A. Kubota, Y. Iwase, K. Sekiya, M. Ubasawa, and S. Yuasa Antiviral activities of MCC-478, a novel and specific inhibitor of hepatitis B virus Antimicrob Agents Chemother 46 2002 2872 2877
10. T. Shaw, D. Colledge, V. Sozzi, and S.A. Locarnini LY582563 (MCC-478), a 2-aminopurine nucleotide analogue, inhibits packaging and replication of HBV genome in vitro Hepatology 38 2003 716A
11. G. Golor, K. Rost, H. Watanabe, D. Soon, S. Lowe, and C. Chan Safety and pharmacokinetics of a novel nucleotide analogue, MCC-478 (LY582563) for the treatment of hepatitis B Antiviral Res 84 2001 A084
12. R.A. de Man, L.M. Wolters, F. Nevens, D. Chua, M. Sherman, and C.L. Lai Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection Hepatology 34 2001 578 582
13. R.J. Gilson, K.B. Chopra, A.M. Newell, I.M. Murray-Lyon, M.R. Nelson, and S.J. Rice A placebo-controlled phase I/II study of adefovir dipivoxil in patients with chronic hepatitis B virus infection J Viral Hepat 6 1999 387 395
14. C.L. Lai, C.K. Ching, A.K. Tung, E. Li, J. Young, and A. Hill Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial Hepatology 25 1997 241 244
15. M. Rizzetto Efficacy of lamivudine in HBeAg-negative chronic hepatitis B J Med Virol 66 2002 435 451
16. M. Saruc, N. Ozden, and H. Yuceyar Thymosin in the treatment of HBeAg-negative chronic hepatitis B Med Sci Monit 9 2003 RA198 RA202
17. C.L. Lai, C.K. Ching, A.K. Tung, E. Li, J. Young, and A. Hill Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: a placebo-controlled trial Hepatology 25 1997 241 244
18. T. Cihlar, E.S. Ho, D.C. Lin, and A.S. Mulato Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs Nucleosides Nucleotides Nucleic Acids 20 2001 641 648
19. D. Colledge, T. Shaw, S. Bowden, S. Locarnini, S. Lewin, and F. Wightman The purine nucleotide analogue LY582563 (MCC-478) inhibits replication of wild type and drug-resistant hepatitis B virus J Hepatol 36 2002 A307
20. S.K. Ono-Nita, N. Kato, Y. Shiratori, F.J. Carrilho, and M. Omata Novel nucleoside analogue MCC-478 (LY582563) is effective against wild-type or lamivudine-resistant hepatitis B virus Antimicrob Agents Chemother 46 2002 2602 2605